Antibiotic Exposure During Pregnancy Affects Infant Gut Microbiota
NCT ID: NCT06479941
Last Updated: 2024-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
450 participants
OBSERVATIONAL
2023-06-25
2024-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of IAP-EOGBSD on Offspring's Gut Microbiome and Immunity.
NCT05738460
Microbiome and Malnutrition in Pregnancy
NCT04992104
Effects of IAP-EOGBSD on Maternal Vaginal Microbiome, Offspring's Gut Microbiome and Metabolites.
NCT05738473
Microbiome, Antibiotics, and Growth Infant Cohort
NCT03001167
Prenatal Antibiotics and Breast Milk / Neonatal IgA
NCT05813184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mother-infant cohort with antibiotic treatment group
E.g., Bacterial infection during pregnancy
antibiotic treatment
AT: Mother-infant cohort with antibiotic treatment group CS: Mother-infant cohort (Prophylactic antibiotics therapy) ND: Mother-infant cohort (Natural delivery)
Mother-infant cohort (Prophylactic antibiotics therapy)
E.g., cesarean section
antibiotic treatment
AT: Mother-infant cohort with antibiotic treatment group CS: Mother-infant cohort (Prophylactic antibiotics therapy) ND: Mother-infant cohort (Natural delivery)
Mother-infant cohort (Natural delivery)
E.g., Natural delivery
antibiotic treatment
AT: Mother-infant cohort with antibiotic treatment group CS: Mother-infant cohort (Prophylactic antibiotics therapy) ND: Mother-infant cohort (Natural delivery)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
antibiotic treatment
AT: Mother-infant cohort with antibiotic treatment group CS: Mother-infant cohort (Prophylactic antibiotics therapy) ND: Mother-infant cohort (Natural delivery)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged 20-40 years old
* natural conception
* single pregnancy
* gestational age ≥36 weeks
2. Newborn
* normal Apgar score
* no serious congenital diseases
Exclusion Criteria
1 Day
12 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
xu xue
Vice Chief Physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Peking University People's Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PKUPH-X2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.